Sex-specific differences in intestinal microbiota associated with cardiovascular diseases/Experiment 4
From BugSigDB
Reviewed Marked as Reviewed by Chloe on 2024-1-25
Subjects
- Location of subjects
- Spain
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Cardiovascular disease [X]Cardiovascular disease, unspecified,[X]Cardiovascular disease, unspecified (disorder),[X]Other forms of heart disease,[X]Other forms of heart disease (disorder),[X]Other ill-defined heart diseases,[X]Other ill-defined heart diseases (disorder),[X]Other specified diseases of pericardium,[X]Other specified diseases of pericardium (disorder),ASCVD,CARDIOVASC DIS,cardiovascular disease,Cardiovascular Disease (CVD),cardiovascular disease (CVD),Cardiovascular disease, NOS,Cardiovascular disease, unspecified,Cardiovascular Diseases,Cardiovascular Disorder,cardiovascular disorder,Cardiovascular disorder, NOS,Cardiovascular Disorders,Cardiovascular system disease,cardiovascular system disease,cardiovascular system disease or disorder,Certain sequelae of myocardial infarction, not elsewhere classified,CIRCULATORY DISEASE NOS,circulatory system disease,Circulatory system disease NOS,Circulatory system disease NOS (disorder),CVD,CVD, NOS,CVS disease,Disease affecting entire cardiovascular system,Disease affecting entire cardiovascular system (disorder),Disease of cardiovascular system,disease of cardiovascular system,Disease of cardiovascular system (disorder),Disease of cardiovascular system, NOS,disease of subdivision of hemolymphoid system,disease or disorder of cardiovascular system,Disease, Cardiovascular,DISEASES OF THE CIRCULATORY SYSTEM,Diseases, Cardiovascular,Disorder of cardiovascular system,disorder of cardiovascular system,Disorder of cardiovascular system (disorder),Disorder of circulatory system,Disorder of circulatory system, NOS,Disorder of the circulatory system,Ill-defined descriptions and complications of heart disease,ILL-DEFINED HRT DIS NEC,Other diseases of endocardium,Other diseases of endocardium (disorder),Other diseases of pericardium,Other diseases of pericardium (disorder),Other disorders of papillary muscle,Other forms of heart disease,Other forms of heart disease (disorder),Other heart disease,Other heart disease (disorder),Other heart disease NOS,Other heart disease NOS (disorder),Other ill-defined heart disease,Other ill-defined heart disease (disorder),Other ill-defined heart disease NOS,Other ill-defined heart disease NOS (disorder),Other ill-defined heart diseases,Other pericardial disease NOS,Other pericardial disease NOS (disorder),OTHER SEQUELAE OF MI NEC,Other sequelae of myocardial infarction, not elsewhere classified,Other specified diseases of pericardium,Other specified pericardial disease NOS,Other specified pericardial disease NOS (disorder),PAPILLARY MUSCLE DIS NEC,PERICARDIAL DISEASE NEC,Unspecified circulatory system disorder,Cardiovascular disease
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Women without cardiovascular disease
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Women with coronary heart disease (CHD)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Women with coronary heart disease, and enrolled in the CORDIOPREV study
- Group 0 sample size Number of subjects in the control (unexposed) group
- 87
- Group 1 sample size Number of subjects in the case (exposed) group
- 112
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 1 month
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- decreased
- Richness Number of species
- unchanged
- Faith Phylogenetic diversity, takes into account phylogenetic distance of all taxa identified in a sample
- unchanged
Signature 1
Reviewed Marked as Reviewed by Chloe on 2024-1-25
Source: Figure 4
Description: Linear discriminant analysis between CHD patients and non‑CVD subjects in Women
Abundance in Group 1: increased abundance in Women with coronary heart disease (CHD)
Revision editor(s): Andre
Signature 2
Reviewed Marked as Reviewed by Chloe on 2024-1-25
Source: Figure 4
Description: Linear discriminant analysis between CHD patients and non‑CVD subjects in Women
Abundance in Group 1: decreased abundance in Women with coronary heart disease (CHD)
Revision editor(s): Andre
